Health Care Newsletter

Supreme Court deals blow to Big Pharma

by Joseph Choi and Nathaniel Weixel - 05/18/26 6:25 PM ET

Link copied

by Joseph Choi and Nathaniel Weixel - 05/18/26 6:25 PM ET

Link copied

Thank you for signing up!

Subscribe to more newsletters here

The latest in politics and policy.

Direct to your inbox.

- Presented by Coalition to Strengthen America’s Healthcare

{beacon}

View Online

Health Care

PRESENTED BY

The Big Story

Supreme Court deals blow to pharma challenge of Medicare price negotiation

The Supreme Court declined to take up petitions from several of the country’s largest pharmaceutical companies challenging the Medicare drug price negotiation program.

The decision leaves several lower court rulings upholding the program that Congress enacted as part of the Biden administration’s Inflation Reduction Act 2022. The justices did not issue comments with the decision.

The drugmakers’ appeals were considered longshots, as the lower courts were almost all in agreement. The Supreme Court often looks for disagreement among lower courts before granting a case.

Other lawsuits over the program are still pending, but the loss by AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Janssen, Novartis, and Novo Nordisk will make those other cases more difficult.

The law requires the government to negotiate prices for certain high-cost drugs in Medicare on an annual basis, with the first deals taking effect in 2026. Drugmakers have been fighting the Medicare negotiation program for years.

The drugmakers said the program violates their due process rights because there is no real negotiation; the companies pay the prices set by the federal government, or they can’t participate in Medicare.

Lower courts have rejected those arguments, noting that the companies are free to pull their products from government health programs.

To date, Medicare has negotiated prices for 25 of the highest cost drugs, including GLP-1 weight-loss and diabetes drugs Ozempic, Rybelsus and Wegovy.

The Trump administration has been highly critical of the Inflation Reduction Act but has taken ownership of the Medicare price negotiation program, embracing efforts to lower drug prices.

Welcome to The Hill’s Health Care newsletter, we’re Nathaniel Weixel and Joseph Choi — every week we follow the latest moves on how Washington impacts your health.

Did someone forward you this newsletter? Subscribe here.

Essential Reads

How policy will be impacting the health care sector this week and beyond:

Trump proposes partial rollback of ‘forever chemical’ drinking water protections

The Trump administration on Monday moved to partially roll back drinking water protections from toxic “forever chemicals.” The Environmental Protection Agency (EPA) proposed to allow some delays for water systems to regulate these chemicals. It also said it would rescind four of the six types of forever chemicals covered under a Biden-era rule. Under that Biden-era regulation, water systems are required to filter out at …

Full Story

 HHS withdraws amended vaccine advisory panel charter

The Department of Health and Human Services (HHS) on Monday withdrew its amended charter for a highly influential vaccine advisory committee that would have loosened eligibility requirements, citing administrative errors. In a notice set to be officially published in the Federal Register, HHS formally withdrew its proposed amendment to the charter for the Advisory Committee on Immunization Practices (ACIP) for the Centers for …

Full Story

 US bans foreign travelers from Ebola-impacted nations

In response to a growing Ebola outbreak, the Centers for Disease Control and Prevention (CDC) on Monday said it is imposing a ban on foreign passport holders from entering the country if they have been in Uganda, Congo or South Sudan in the previous 21 days. The order comes as the CDC confirmed an American physician working in the outbreak zone tested positive for the virus. The doctor is being transported to Germany, along …

Full Story

On Our Radar

Upcoming news themes and events we’re watching:

The Senate Committee on Health, Education, Labor, and Pensions will hold a hearing Thursday on gender transition procedures on minors.

 CONTENT FROM OUR SPONSOR

Your care shouldn’t be put on hold

When insurers delay approvals or require endless paperwork, patients are left waiting for care they need now. Addressing harmful corporate insurer practices can help ensure timely access to treatment and protect 24/7 care. Learn more

In Other News

Branch out with a different read from The Hill:

Hantavirus-stricken cruise ship docks in the Netherlands for dis